Compare Cytokinetics Inc (CYTK) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Fidelity National Information Servcs Inc — how do they compare? Cytokinetics Inc trades at $62.72 (market cap $8.62B), while Fidelity National Information Servcs Inc trades at $33.98 (market cap $17.71B). The key difference: Fidelity National Information Servcs Inc is far larger — about 2.1× Cytokinetics Inc's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Fidelity National Information Servcs Inc for 88 Days on average.
| CYTK | FIS | |
|---|---|---|
Market Cap | $8.62B | $17.71B |
Volume | 2,594,626 | 9,047,825 |
Sector | Health | Technology |
52-Week High | $87.26 | $68.57 |
52-Week Low | $54.76 | $32.44 |
Typical Hold Time | 19 Days | 88 Days |
Enterprise Value | $8.72B | $38.22B |
Dividend Yield | — | 5.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
FIS trades at $34.19, up 1.09% with bearish technical signals but strong fundamentals including a low P/E of 5.27 and net income margin of 27.65%. Recent earnings show mixed results with Q1 and Q2 beats but a Q4 miss. The company demonstrates business momentum with multiple core banking wins and product launches, including embedded banking platform and cloud modernization initiatives announced in September 2026.
FIS presents a compelling value opportunity with attractive valuation metrics and improving profitability, though technical indicators suggest near-term pressure. The 37% upside to consensus price target of $47.15 and strong analyst support (57% buy ratings) indicate Wall Street optimism, balanced by debt concerns and competitive fintech landscape requiring careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
